ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
AnaptysBio Inc

AnaptysBio Inc (ANAB)

37.53
0.96
(2.63%)
At close: September 19 4:00PM
37.53
0.01
( 0.03% )
After Hours: 4:27PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
37.53
Bid
25.00
Ask
40.40
Volume
297,702
37.12 Day's Range 39.50
13.36 52 Week Range 41.3083
Market Cap
Previous Close
36.57
Open
37.23
Last Trade Time
16:36:51
Financial Volume
$ 11,270,967
VWAP
37.8599
Average Volume (3m)
315,179
Shares Outstanding
30,184,531
Dividend Yield
-
PE Ratio
-6.92
Earnings Per Share (EPS)
-5.42
Revenue
17.16M
Net Profit
-163.62M

About AnaptysBio Inc

AnaptysBio Inc is clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery techno... AnaptysBio Inc is clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product candidates are ANB020, ANB019, and Checkpoint receptor agonist. The entity generates revenue from the collaborative research and development arrangements. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
-
AnaptysBio Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ANAB. The last closing price for AnaptysBio was $36.57. Over the last year, AnaptysBio shares have traded in a share price range of $ 13.36 to $ 41.3083.

AnaptysBio currently has 30,184,531 shares outstanding. The market capitalization of AnaptysBio is $1.10 billion. AnaptysBio has a price to earnings ratio (PE ratio) of -6.92.

ANAB Latest News

Anaptys Announces Participation in September Investor Conferences

SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced...

Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering

SAN DIEGO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced the...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
11.714.7738693467335.8240.735.41535049138.65298506CS
4-0.29-0.7667900581737.8240.734.376925408737.47877913CS
1213.1754.064039408924.3641.308323.7231517934.24437618CS
2614.5263.102998696223.0141.308318.4934761127.6670456CS
5218.3695.774647887319.1741.308313.3630442924.57156096CS
15610.9140.984222389226.6241.308313.3626273124.50057364CS
260-5.27-12.313084112142.843.10229.1633291521.8248109CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
LFLYLeafly Holdings Inc
$ 3.78
(111.17%)
4.68M
AENTAlliance Entertainment Holding Corporation
$ 2.80
(37.25%)
122.42k
TNONTenon Medical Inc
$ 6.45
(28.23%)
2.7M
AEMDAethlon Medical Inc
$ 0.4949
(26.90%)
8.43M
LDTCLeddarTech Holdings Inc
$ 0.3649
(22.45%)
180.12k
EJHE Home Household Service Holdings Ltd
$ 0.077
(-21.11%)
8.68M
KOPNKopin Corporation
$ 0.8004
(-16.98%)
191.23k
NCINeo Concept International Group Holdings Ltd
$ 0.74
(-11.90%)
1.57M
RZLVRezolve AI Ltd
$ 6.3022
(-9.97%)
40.17k
ARQArq Inc
$ 5.58
(-9.56%)
87.77k
EJHE Home Household Service Holdings Ltd
$ 0.077
(-21.11%)
8.68M
AEMDAethlon Medical Inc
$ 0.50
(28.21%)
8.43M
HSTHost Hotels and Resorts Inc
$ 18.53
(0.00%)
6.45M
LFLYLeafly Holdings Inc
$ 3.78
(111.17%)
4.68M
SQQQProShares UltraPro Short QQQ
$ 7.79
(0.39%)
4.62M

ANAB Discussion

View Posts
Monksdream Monksdream 4 days ago
ANAB definite uptrend
πŸ‘οΈ0
gfp927z gfp927z 2 years ago
HighPeaks, The NY Times article was high profile, but the connection to ANAB isn't readily apparent.

Even with the partial sale/monetization of the revenue stream from dostarlimab in December, the drug is also being studied by Glaxo for other cancer types (endometrial, non-small cell lung, ovarian, and mismatch repair deficient solid tumors). One question to answer is whether the monetization deal with Sagard was only for colorectal, or for all the indications? Probably for all, but I'll have to do more research.

ANAB has numerous other programs and a large pile of cash, so looks interesting. But investing in biotech requires a ton of research, but even then you still don't know what you have, and landmines are everywhere. Better to invest in 'what you know', as Buffett recommends :o)




---
πŸ‘οΈ0
HighPeaks HighPeaks 2 years ago
Thanks TP. Yeah this has the potential to really be a big mover. So surprised no one has made the connection between this potential miracle drug and $ANAB receiving royalties on it(as it’s originator). GSK is the collaborator who has just commercialized it but it’s ANAB invention.
πŸ‘οΈ0
tedpeele tedpeele 2 years ago
Tremendous find HighPeaks. .You have been early on quite a few big movers. I'm thinking this is yet another one.

Will be watching this closely...thanks.
πŸ‘οΈ0
HighPeaks HighPeaks 2 years ago
According to this link ANAB gets 8-25% royalties from Dostarlimab. This drug has recently shown phenomenal results in a trial at Memorial Sloan Kettering Hospital. All patients fully recovered from rectal cancer.
https://www.globenewswire.com/fr/news-release/2020/10/26/2114250/0/en/AnaptysBio-and-GlaxoSmithKline-Amend-Strategic-Immuno-Oncology-Collaboration.html
πŸ‘οΈ0
TFMG TFMG 4 years ago

$ANAB | #Anaptysbio Spikes After Drug Designation


Nice spike in the afterhours session, lets hope we
can get some continuation tomorrow.
Target $29.00 to Fib Golden Pocket
Also a very large gap to fill at $35.00
AnaptysBio gets orphan drug designation of imsidolimab for pustular psoriasis
PLEASE GIVE US A LIKE IF YOU FIND OUR CONTENT HELPFUL, THANK YOU.


πŸ‘οΈ0
LoveItInBishop LoveItInBishop 5 years ago
RSI @ 16. laughable. Zacks has positive take. https://finance.yahoo.com/news/anaptysbio-enters-oversold-territory-135501475.html
πŸ‘οΈ0
ClayTrader ClayTrader 5 years ago
* * $ANAB Video Chart 11-13-19 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
ClayTrader ClayTrader 5 years ago
* * $ANAB Video Chart 11-08-19 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
waterchaser waterchaser 5 years ago
LOL! Twitter PnD. Buyer beware.
πŸ‘οΈ0
420man 420man 5 years ago
Once the real bounce starts it will be fast....
πŸ‘οΈ0
Crazy Money Crazy Money 5 years ago
$10 to da moon
πŸ‘οΈ0
420man 420man 5 years ago
This will bounce..... 15 AH
πŸ‘οΈ0
RJ Trotts RJ Trotts 5 years ago
trying to bounce back over $11, hoping for more
πŸ‘οΈ0
TaxiCaT TaxiCaT 5 years ago
Ouch -
πŸ‘οΈ0
celle celle 5 years ago
Nothing happen here?
πŸ‘οΈ0
manny371 manny371 7 years ago
This stock is making noise! Bought in Sept $ANAB
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock